AU2245695A - Composition for treating neurological disorders - Google Patents

Composition for treating neurological disorders

Info

Publication number
AU2245695A
AU2245695A AU22456/95A AU2245695A AU2245695A AU 2245695 A AU2245695 A AU 2245695A AU 22456/95 A AU22456/95 A AU 22456/95A AU 2245695 A AU2245695 A AU 2245695A AU 2245695 A AU2245695 A AU 2245695A
Authority
AU
Australia
Prior art keywords
composition
neurological disorders
treating neurological
treating
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22456/95A
Inventor
Joel Saydoff
Robert Zaczek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of AU2245695A publication Critical patent/AU2245695A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU22456/95A 1994-04-11 1995-04-10 Composition for treating neurological disorders Abandoned AU2245695A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22587494A 1994-04-11 1994-04-11
US225874 1994-04-11
US41754095A 1995-04-06 1995-04-06
US417540 1995-04-06
PCT/US1995/004423 WO1995027489A1 (en) 1994-04-11 1995-04-10 Composition for treating neurological disorders

Publications (1)

Publication Number Publication Date
AU2245695A true AU2245695A (en) 1995-10-30

Family

ID=26919993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22456/95A Abandoned AU2245695A (en) 1994-04-11 1995-04-10 Composition for treating neurological disorders

Country Status (2)

Country Link
AU (1) AU2245695A (en)
WO (1) WO1995027489A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262081B1 (en) * 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
GB201521541D0 (en) * 2015-12-07 2016-01-20 Proximagen Ltd New therapeutic uses of enzyme inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2037178A1 (en) * 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
US5171745A (en) * 1990-07-13 1992-12-15 Du Pont Merck Pharmaceutical Company Method of treating neurological dysfunction using neutrotransmitter enhancers

Also Published As

Publication number Publication date
WO1995027489A1 (en) 1995-10-19

Similar Documents

Publication Publication Date Title
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
AU3153295A (en) Methods for treating addictive disorders
AU1128297A (en) Composition for treating pain
AU2595397A (en) Apparatus for treating neurodegenerative disorders
IL121170A0 (en) Compositions for the treatment of dermatological disorders
HUP0001237A3 (en) Methods for treating vascular disorders
HUP9904525A3 (en) Pharmaceutical compositions for the treatment of neurological disorders comprising s-(-)-n-propargyl-1-amino indan
PL336290A1 (en) Sulphonamides for treating endothelin-involving disorders
EP0703282A3 (en) Composition for surface treatment
AU4868599A (en) Composition for and method of treating neurological disorders
AU7582398A (en) Composition for treating skin conditions
AU1139095A (en) Combination treatment for osteoporosis
AUPO274596A0 (en) Method for the treatment of neurological or neuropsychiatric disorders
AU1542895A (en) Surface treatment
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
AU5787999A (en) Method for treating neurodegenerative disorders
AU2557895A (en) Composition for treating gastrointestinal disorders
PL332821A1 (en) Pyrazolydinones for treating potency disorders
AUPM456894A0 (en) Treatment for gastric disorders
PL322625A1 (en) Benzamides for treating neurodegenerative disorders
AU2705195A (en) Incontinence treatment
IL124419A0 (en) Composition for treating pain
AU7018794A (en) Methods for treating pathologies
AU6966998A (en) Composition for treating pain